Skip to main content
SpringerLink
Log in

Cardiopulmonary effects and safety of prostaglandin E1: A review

  • Original Articles
  • Published:
International Journal of Angiology

Abstract

Intraarterial and intravenous infusion of prostaglandin E1 (PGE1) is established treatment for severe peripheral arterial occlusive disease, particularly in Europe and Japan. In this critical appraisal, experimental and clinical studies are reviewed, with special emphasis on cardiopulmonary effects and drug safety. The pulmonary data all indicate dose-dependent dilation of the pulmonary vessels with a reduction in pulmonary resistance. The known hemodynamic effects of PGE1 on the heart include an increase in stroke volume, cardiac index, and left ventricular ejection fraction, and a reduction in left ventricular filling pressure. Analysis of clinical trials shows a low rate of adverse effects, in particular a low incidence of cardiopulmonary side effects. If the recommendations for high-risk patients are observed, PGE1 is both an efficacious and safe therapeutic principle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bergström S, Ryhage R, Samuelsson B, et al (1963) Prostaglandins and related factors. The structure of prostaglandin E1, F1α and F1β. J Biol Chem 238:3555–3564.

    PubMed  Google Scholar 

  2. Gruss JD, Vargas-Montano H, Bartels D, Simmenroth HW, Sakurai T, Schäfer G, Fietze-Fischer B (1984) Use of prostaglandins in arterial occlusive diseases. Inter Angio 3 (suppl):7–17.

    Google Scholar 

  3. Gryglewski RJ (1984) Prostacyclin. Pharmacology and clinical trials. Inter Angio 3(suppl):89–97.

    Google Scholar 

  4. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665.

    Article  PubMed  Google Scholar 

  5. Simmet Th, Peskar BA (1988) Prostaglandin E1 and arterial occlusive disease: Pharmacological considerations. Eur J Clin Invest 18:549–554.

    PubMed  Google Scholar 

  6. Vane JR (1984) Prostacyclin in the cardiovascular system in health and disease. In: Prostaglandins and Other Eicosanoids in the Cardiovascular Systems, Schrör K (ed). Proc 2nd Int Symp Nürnberg-Fürth, Karger: Basel, pp 7–28.

    Google Scholar 

  7. Diehm C (1993) Review of clinical data with PGE1 in critical limb ischaemia. Crit Ischaemia 3(suppl 1):31–37

    Google Scholar 

  8. Heidrich H, Breddin K, Rudofsky G, Scheffler P (1992) Kardiopulmonale Wirkungen von Prostaglandin E1—Aspekte zur Arzneimittelsicherheit. Med Klin 87:123–130.

    PubMed  Google Scholar 

  9. Sinzinger H (1984) Prostaglandin synthesis and metabolism. Physiology and pathophysiology. Inter Angio 3(suppl):19–24.

    Google Scholar 

  10. Schrör K (1991) Cellular sites of action of prostaglandins in the cardiovascular system. In: Prostaglandin E1. New Aspects on Pharmacology, Metabolism and Clinical Efficacy, Diehm C, Sinzinger H, Rogatti W (eds). Springer-Verlag: Berlin, Heidelberg, pp 1–5.

    Google Scholar 

  11. Lumley Ph, Humphrey PPA, Kennedy I, et al (1982) Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog. Eur J Pharmacol 81:421–430.

    Article  PubMed  Google Scholar 

  12. Heidrich H, Brodel Ch, Meuche Ch, et al (1991) Kontrollierte Blutdrucklangzeitmessung unter intravenöser Prostaglandin E1-infusion. Vasa 20:13–16.

    PubMed  Google Scholar 

  13. Ehrly AM, Schenk J, Sager-Lorenz K (1987) Einfluß einer intravenösen Gabe von Prostaglandin E1 auf den Muskelgewebesauerstoffdruck, die transkutanen Gasdruckwerte und die Fließeigenschaften des Blutes von Patienten im Stadium III und IV der chronischen arteriellen Verschlußkrankheit. VASA 20(suppl):196–198.

    Google Scholar 

  14. Scheffler P, de la Hamette D, Leipnitz G (1989) Therapeutic efficacy of intravenously applied prostaglandin E1. VASA 28(suppl):19–25.

    Google Scholar 

  15. Wilkens JH, Wilkens H, Elger B, et al (1987) Cardiac and microcirculatory effects of different doses of prostaglandin E1 in man. Eur J Clin Pharmacol 33:133–137.

    Article  PubMed  Google Scholar 

  16. Prielipp RC, Rosenthal MH, Pearl RG (1988) Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in vasoconstrictor pulmonary hypertension in sheep. Anesth Analg 67:722–729.

    PubMed  Google Scholar 

  17. Schrör K (1984) Prostaglandine und Verwandte Verbindungen. Georg Thieme Verlag: Stuttgart, pp 101–125.

    Google Scholar 

  18. Swan PK, Tibballs J, Duncan AW (1986) Prostaglandin E1 in primary pulmonary hypertension. Critical Care Med 14:72–73.

    Google Scholar 

  19. Weir EK, Reeves JT, Grover RF (1975) Prostaglandin E1 inhibits the pulmonary vascular pressor response to hypoxia and prostaglandin E2. Prostaglandins 10:623–631.

    PubMed  Google Scholar 

  20. Appel PL, Shoemaker WC (1984) Hemodynamic and oxygen transport effects of prostaglandin E1 in patients with adult respiratory distress syndrome. Crit Care Med 12:528–529.

    PubMed  Google Scholar 

  21. Leeman M, Lejeune P, Mélot C, et al (1988) Pulmonary vascular pressure-flow plots in canine oleic acid pulmonary edema. Am Rev Respir Dis 138:362–367.

    PubMed  Google Scholar 

  22. Shoemaker WC, Appel PL (1986) Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery 99:275–283.

    PubMed  Google Scholar 

  23. Sinzinger H, Fitscha P (1987) Influence of PGE1 on in-vivo accumulation of radiolabelled platelets and LDL on human arteries. VASA 17(suppl):5–10.

    Google Scholar 

  24. Heymann MA (1981) Pharmacologic use of prostaglandin E1 in infants with congenital heart disease. Am Heart J 837–843.

  25. Ducas J, Light RB, Girling L, et al (1988) Effects of prostaglandin E1 on the pulmonary vascular pressure-flow relationship in canine pulmonary hypertension. J Crit Care 3:24–31.

    Article  Google Scholar 

  26. Bihari DJ, Tinker J (1988) The therapeutic value of vasodilator-prostaglandins in multiple organ failure associated with sepsis. Intensive Care Med 15:2–7.

    Article  PubMed  Google Scholar 

  27. Holcroft JW, Vassar MW, Weber CJ (1986) Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. Ann Surg 203:371–378.

    PubMed  Google Scholar 

  28. Shoemaker WC (1987) Effectiveness of prostaglandin E1 in adult respiratory distress syndrome. Prog Clin Biol Res 236A:361–368.

    PubMed  Google Scholar 

  29. Slotman GJ, Kerstein MD, Bone RC et al (1992) The prostaglandin E1 study group: The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. J Trauma 32:480–489.

    PubMed  Google Scholar 

  30. Tokioka H, Kobayashi Y, Ohta T, et al (1985) The acute effect of prostaglandin E1 on the pulmonary circulation and oxygen delivery in patients with the adult respiratory distress syndrome. Intensive Care Med 11:61–64.

    Article  PubMed  Google Scholar 

  31. Radermacher P, Santak B, Becker H, et al (1989) Prostaglandin E1 and nitroglycerine reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70:601–606.

    PubMed  Google Scholar 

  32. Heerdt PM, Weiss CI (1990) Prostaglandin E1 and intrapulmonary shunt in cardiac surgical patients with pulmonary hypertension. Ann Thorac Surg 49:463–465.

    PubMed  Google Scholar 

  33. Heerdt PM, Yee LL (1989) Differential effect of prostaglandin E1 and sodium nitroprusside on intrapulmonary shunt fraction in a cardiac transplantion patient. Anesth Analg 69:665–667.

    PubMed  Google Scholar 

  34. Gaßner A, Sommer G, Fridrich L, et al (1988) Der Einfluß von Prostaglandin E1 (Alprostadil) auf die pulmonale Hypertonie bei Patienten mit chronisch obstruktiven Atemwegserkrankungen (COPD). Prax Klin Pneumol 42:521–524.

    PubMed  Google Scholar 

  35. Wohlt G, Meissner E, Fabel H (1991) Der Abfall des arteriellen pO2 während intravenöser PGE1-Infusion ist bei Patienten mit COPD klinisch relevant. Klin Wochenschr 69:306.

    Article  Google Scholar 

  36. Naeije R, Melot C, Mols P, et al (1982) Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 125:1–5.

    Google Scholar 

  37. Issekutz AC, Movat HZ (1982) The effect of vasodilator prostaglandins on polymorphonuclear leukocyte infiltration and vascular injury. Am J Pathol 107:300–309.

    PubMed  Google Scholar 

  38. Lindbom L, Hedqvist P, Dahlén S.-E, et al (1982) Leukotriene B4 induces extravasation and migration of polymorphonuclear leukocytes in vivo. Acta Physiol Scand 116:105–108.

    PubMed  Google Scholar 

  39. Weissmann G, Smolen JE, Korchak HM (1980) Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 303:27–34.

    PubMed  Google Scholar 

  40. Dahlen S.-E (1983) Pulmonary effects of leukotrienes. Acta Physiol Scand 512(suppl):1–51.

    Google Scholar 

  41. Bray MA, Cunningham FM, Ford-Hutchinson AW, et al (1981) Leukotriene B4: Mediator or vascular permeability. Br J Pharmac 72:483–486.

    Google Scholar 

  42. Di Marzo V, Tippins JR, Morris HR (1987) Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: Effect of prostaglandins E1 and F1. Biochem Biophys Res Commun 147:1213–1218.

    Article  PubMed  Google Scholar 

  43. Ney P, Schrör K (1989) E-type prostaglandins but not iloprost inhibit platelet activating factor-induced generation of leukotriene B4 by human polymorphonuclear leukocytes. Br J Pharmacol 96:186–192.

    PubMed  Google Scholar 

  44. O'Flaherty JT, Kreutzer DL, Ward PA (1979) Effect of prostaglandins E1, E2 and F2α on neutrophil aggregation. Prostaglandins 17:201–210.

    Article  PubMed  Google Scholar 

  45. Gillespie MN, Moore CG, Wright CE, et al (1987) Salutary effects of prostaglandin E1 in perfused rat lungs injured with hydrogen peroxide. J Pharmacol Exp Ther 241:1–5.

    PubMed  Google Scholar 

  46. Auinger Ch, Weissel M, Bergmann H, et al (1988) Einfluß von PGE1 auf die linksventrikuläre Auswurffraktion. Wiener Klinische Wschr 21:706–709.

    Google Scholar 

  47. Awan NA, Evenson MK, Needham KE, et al (1981) Cardiocirculatory and myocardial energetic effects of prostaglandin E1 in severe left ventricular failure due to chronic coronary heart disease. Am Heart J 102:703–709.

    Article  PubMed  Google Scholar 

  48. Pacher R, Globits S, Sochor H, et al (1990) Prostaglandin E1 verbessert die hämodynamik bei fortgeschrittener herzinsuffizienz. Ztschr f Kardiol 79(suppl):22.

    Google Scholar 

  49. Popat KD, Pitt B (1982) Hemodynamic effects of prostaglandin E1 infusion in patients with acute myocardial infarction and left ventricular failure. Am Heart J 103:485–489.

    Article  PubMed  Google Scholar 

  50. Virgolini I, Auinger C, Weissel M, et al (1989) Increase in left ventricular ejection fraction (LVEF) induced by PGE1 and PGI2. In: Prostaglandins in Clinical Research: Cardiovascular System. Alan R. Liss Verlag: New York, pp 463–467.

    Google Scholar 

  51. Cámara ML, Aris A, Alvarez J, et al (1992) Hemodynamic effects of prostaglandin E1 and isoproterenol early after cardiac operations for mitral stenosis. J Thorac Cardiovasc Surg 103:1177–1185.

    PubMed  Google Scholar 

  52. Iberer F, Wasler A, Tscheliessnigg KH, et al (1991) Prostaglandin E1 in der Herztransplantation—Prävention des Rechtsherzversagens und der Abstoßung. Z Herz- Thorax-, Gefäßchir 5:33–37.

    Google Scholar 

  53. Vincent JL, Carlier E, Pinsky MR et al (1992) Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation. J Thoracic Cardiovasc Surg 103:33–39.

    Google Scholar 

  54. Sharma B, Wyeth RP, Gimenez HJ, et al (1986) Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. Am J Cardiol 58:1961–1966.

    Article  Google Scholar 

  55. Siegel RJ, Shah PK, Nathan M, et al (1984) Prostaglandin E1 infusion in unstable angina: Effects on anginal frequency and cardiac function. Am Heart J 108:863–868.

    Article  PubMed  Google Scholar 

  56. Feldmann RL, Rose B, Verbust KM (1988) Hemodynamic and angiographic effects of prostaglandin E1 in coronary artery disease. Am J Cardiol 62:698–702.

    Article  PubMed  Google Scholar 

  57. Ramanathan I, Wilson JL (1989) Effect of PGE1 on transmyocardial distribution of coronary and collateral blood flow—absence of coronary steal. Clin Res 1:29A.

    Google Scholar 

  58. Thiemermann Ch, Schrör K (1988) Kardioprotektive Wirkung von Prostaglandin E1 auf das reperfundierte ischämische Myokard im Tierversuch. In: Prostaglandin E1—Wirkungen und Therapeutische Wirksamkeit, Heidrich H, Böhme H, Rogatti W (eds). Springer-Verlag: Berlin, pp 34–44.

    Google Scholar 

  59. Kannel WB, Skinner JR, Schwartz MJ, et al (1970) Intermittent claudication: Incidence in the Framingham study. Circulation 41:875–883.

    PubMed  Google Scholar 

  60. Müller-Bühl U, Diehm C, Sieben U, et al (1987) Prävalenz und Risikofaktoren von peripher-arterieller Verschlußkrankheit und koronarer Herzkrankheit. Vasa 21(suppl):4–46.

    Google Scholar 

  61. Nobbe F (1983) Der angiologische Risikopatient aus internistischer Sicht. In: Probleme der Vor—und Nachsorge und der Narkoseführung bei Invasiver Angiologischer Diagnostik und Therapie. Begutachtung Arterieller und Venöser Gefäßschäden, Pflaum Verlag: München, pp 11–20.

    Google Scholar 

  62. Balzer K, Rogatti W, Rüttgerodt K (1989) Therapeutische Wirksamkeit von Prostaglandin E1—intraarterielle und intravenöse PGE1-therapie bei AVK im Stadium III/IV. Therapiewoche 39:2736–2742.

    Google Scholar 

  63. Blume J (1987) Klinische Wirksamkeit der intraarteriellen Infusionstherapie mit Prostaglandin E1 im Stadium IIb der arteriellen Verschlußkrankheit. Therapiewoche 37:4819–4823.

    Google Scholar 

  64. Böhme H, Brülisauer M, Härtel U, et al (1989) Periphere arterielle Verschlußkrankheit im Stadium III und IV—kontrollierte Zweizentren-studie zur Wirksamkeit von intraarteriellen Prostaglandin E1-infusionen. Med Welt 40:1501–1503.

    Google Scholar 

  65. Creutzig A, Caspary L, Radeke U, et al (1988) Prospektive randomisierte Doppelblindstudie zur Wirksamkeit von i.a. Prostaglandin E1 bei der schweren claudicatio intermittens. In: Prostaglandin E1—Wirkungen und Therapeutische Wirksamkeit, Heidrich H, Böhme H, Rogatti W (eds). Springer-Verlag: Berlin, Heidelberg, New York, pp 95–102.

    Google Scholar 

  66. Rudofsky G, Altenhoff B, Meyer P, et al (1987) Intra-arterial perfusion with prostaglandin E1 in patients with intermittent claudication. VASA 17(suppl):47–51.

    Google Scholar 

  67. Trübestein G, Ludwig M, Diehm C, et al (1987) Prostaglandin E1 bei arterieller Verschlußkrankheit im Stadium III und IV—Ergebnisse einer multizentrischen Studie. DMW 112:955–959.

    Google Scholar 

  68. Diehm C, Hübsch-Müller C, Stammler F (1988) Intravenöse Prostaglandin E1—therapie bei Patienten mit peripherer arterieller Verschlußkrankheit (AVK) im Stadium III—eine doppelblinde, plazebo-kontrollierte Studie. In: Prostaglandin E1—Wirkungen und Therapeutische Wirksamkeit, Heidrich H, Böhme H, Rogatti W (eds). Springer-Verlag: Berlin, Heidelberg, New York, pp 133–143.

    Google Scholar 

  69. Diehm C, Kühn A, Strauss R, et al (1989) Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication. VASA 28(suppl):26–30.

    Google Scholar 

  70. Heidrich H, Ranft J, Peters A, et al (1987) Früh-und spätergebnisse nach intravenöser PROSTAVASIN-therapie bei peripherarteriellen Durchblutungsstörungen mit Ruheschmerz und Nekrose. VASA 20(suppl):202–203.

    Google Scholar 

  71. Rudofsky G (1988) Intravenöse PGE1-infusionsbehandlung bei Patienten mit arterieller Verschlußkrankheit im Stadium IIb. In: Prostaglandin E1—Wirkungen und Therapeutische Wirksamkeit, Heidrich H, Böhme H, Rogatti W (eds). Springer-Verlag: Berlin, Heidelberg, New York, pp 103–111.

    Google Scholar 

  72. Stiegler H, Diehm C, Grom E, et al (1992) Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV. VASA 35(suppl):164–166.

    Google Scholar 

  73. Trübestein G, v. Bary S, Breddin K, et al (1989) Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease—a controlled randomised multicenter study. VASA 28(suppl):44–49.

    Google Scholar 

  74. Rudofsky G (1988) Kompaktwissen Angiologie. Perimed Verlag: Erlangen, 284–303.

    Google Scholar 

  75. Heidrich H, Schumacher T Kardiopulmonales risikoprofil von PGE1 bei i.v. applikation. Retrospektive Analyse von 426 Patienten mit peripherer arterieller Verschlußkrankheit. (in press).

  76. Lynch TG, Hobson RW, Barbalinardo JP, et al (1984) Effects of intravenous and intra-arterial infusions of prostaglandin E1 on canine hindlimb blood flow distribution. Surgery 96:35–41.

    PubMed  Google Scholar 

  77. Emmons PR, Hampton JR, Harrison MJG, et al (1967) Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J 2:468–472.

    PubMed  Google Scholar 

  78. Kloeze J (1969) Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim Biophys Acta 187:285–292.

    PubMed  Google Scholar 

  79. Fantone JC, Kunkel SL, Ward PA, et al (1981) Suppression of human polymorphonuclear leukocyte function after intravenous infusion of prostaglandin E1 Prostaglandins Med 2: 195–198.

    Google Scholar 

  80. Hecker G, Ney P, Schrör K (1990) Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2. Naunyn-Schmiedeberg's Arch Pharmacol 341:308–315.

    Article  Google Scholar 

  81. Neumann FJ, Diehm C, Müller-Bühl U, et al (1989) Einfluß von Prostaglandin E1 auf Funktion und Verformbarkeit neutrophiler granulozyten bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium IV. VASA 27(suppl):40–41.

    Google Scholar 

  82. Sinzinger H (1986) Inhibition of mitotic and proliferative activity of smooth muscle cells by Prostaglandin E1. In: Prostaglandin E1 in Atherosclerosis. Sinzinger H, Rogatti W (eds). Springer-Verlag: Heidelberg, 39–48.

    Google Scholar 

  83. Sinzinger H, Fitscha P, Wagner O, et al (1986) Prostaglandin E1 decreases activation of arterial smooth-muscle cells. Lancet II: 156–157.

    Article  Google Scholar 

  84. Sinzinger H, Zidek T, Rogatti W (1988) PGE1 reduces collagen and glycosaminoglycan synthesis in rabbit aorta. Exp Pathol 33:119–122.

    PubMed  Google Scholar 

  85. Crutchley DJ, Conanan LB, Maynard JR (1982) Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2. J Pharmacol Exp Ther 222:544–549.

    PubMed  Google Scholar 

  86. Tilsner V (1988) Aktivierung der endogenen Fibrinolyse durch Prostaglandin E1. In: Prostaglandin E1—Wirkungen und Therapeutische Wirksamkeit, Heidrich H, Böhme H, Rogatti W (eds). Springer-Verlag: Berlin, pp 76–82.

    Google Scholar 

  87. Kury PG, Ramwell PW, McConnel HM (1974) The effect of prostaglandin E1 and E2 on the human erythrocyte as monitored by spin labels. Biochem Biophys Res Commun 56:478–483.

    Article  PubMed  Google Scholar 

  88. Rudofsky G (1986) The effect of intra-arterial and intravenous prostaglandin E1 in a model of ischaemia in healthy volunteers. In: Prostaglandin E1 in Atherosclerosis, Sinzinger H, Rogatti W (eds). Springer-Verlag: Berlin, pp 49–53.

    Google Scholar 

  89. Creutzig A, Creutzig H, Alexander K (1986) Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease. Eur J Clin Invest 16:480–485.

    PubMed  Google Scholar 

  90. Heidrich H, Lammersen T (1985) Vitalkapillarmikroskopische Untersuchungen nach intravenöser Prostaglandin E1-infusion. DMW 110:1283–1285.

    Google Scholar 

  91. Rexroth W, Amendt K, Römmele U, et al (1985) Effekte von Prostaglandin E1 auf Hämodynamik und Extremitätenstoffwechsel bei Gesunden und Patienten mit arterieller Verschlußkrankheit Stadium III und IV. VASA 14:220–224.

    PubMed  Google Scholar 

  92. Stiegler H, Rett K, Wicklmayr M, et al (1989) Metabolic effects of prostaglandin E1 on human skeletal muscle with special regard for the amino acid metabolism. VASA 28(suppl):14–18.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. J.-W. Goethe University, Frankfurt, Germany

    Hans Klaus Breddin M.D.

  2. University of Essen, Essen, Germany

    Gottfried Rudofsky M.D.

  3. University of Saarland, Homburg, Germany

    Peter Scheffler M.D.

  4. Chefarzt f. Innere Medizin, Franziskus-Krankenhaus Berlin, Budapester Straße 15-19, 10787, Berlin, Germany

    Heinz Heidrich M.D. (F.I.C.A., Prof. Dr. med.)

Authors
  1. Heinz Heidrich M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Klaus Breddin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gottfried Rudofsky M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Scheffler M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Heidrich, H., Breddin, H.K., Rudofsky, G. et al. Cardiopulmonary effects and safety of prostaglandin E1: A review. International Journal of Angiology 3, 160–168 (1994). https://doi.org/10.1007/BF02014937

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02014937

Keywords

Search

Navigation